12 Best Psychedelic Stocks to Buy in 2025

6. Sage Therapeutics, Inc. (NASDAQ:SAGE)

Number of Hedge Fund Holders: 27 

Sage Therapeutics, Inc. (NASDAQ:SAGE) is a biopharmaceutical company developing treatments for brain health disorders, focusing on the GABA and NMDA receptor systems. Its flagship product, Zulresso, is the first FDA-approved treatment for postpartum depression. The company also generates revenue from its newly approved medication, Zurzuvae, as well as research collaborations and pharmaceutical partnerships.

In 2024, Zurzuvae became the first licensed oral medication for postpartum depression (PPD) in adults, and Sage Therapeutics, Inc. (NASDAQ:SAGE), one of the best psychedelic stocks, saw great success with its early commercialization. Despite fewer days in the field because of the Christmas season, about 2,500 prescriptions of Zurzuvae were shipped during the fiscal fourth quarter of 2024, a 21% increase from the third quarter. Furthermore, approximately 6,600 prescriptions were shipped during the course of the year, demonstrating a robust increase in demand.

To reach more healthcare providers, Sage Therapeutics, Inc. (NASDAQ:SAGE) intends to invest in a combined sales force growth. Through social media and direct-to-consumer initiatives, including possible branded TV media, it also intends to invest in media possibilities to raise awareness and amplify the message that PPD is a serious medical condition.